Autocrine MMP-2/9 secretion increases the BBB permeability in neuromyelitis optica

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 85, Issue 4, 2014, Pages 419-430

  Tasaki, Ayako ^a   Shimizu, Fumitaka ^a   Sano, Yasuteru ^a   Fujisawa, Miwako ^a   Takahashi, Toshiyuki ^b   Haruki, Hiroyo ^a   Abe, Masaaki ^a   Koga, Michiaki ^a   Kanda, Takashi ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 4 ANTIBODY; CLAUDIN 5; GELATINASE A; GELATINASE B; IMMUNOGLOBULIN G; MESSENGER RNA; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ANTIBODY TITER; ARTICLE; AUTOCRINE EFFECT; BLOOD BRAIN BARRIER; BRAIN CAPILLARY ENDOTHELIAL CELL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME RELEASE; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; INFLAMMATORY CELL; LONGITUDINALLY EXTENSIVE TRANSVERSE MYELITIS; MEMBRANE DAMAGE; MEMBRANE PERMEABILITY; MOLECULAR PATHOLOGY; MYELITIS; MYELOOPTIC NEUROPATHY; NEUROMYELITIS OPTICA SPECTRUM DISORDER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; UPREGULATION;

BLOOD-BRAIN BARRIER; MULTIPLE SCLEROSIS;

ADULT; AQUAPORIN 4; AUTOANTIBODIES; BLOOD-BRAIN BARRIER; CASE-CONTROL STUDIES; CELLS, CULTURED; CLAUDIN-5; DIPEPTIDES; ENDOTHELIAL CELLS; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASE INHIBITORS; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROMYELITIS OPTICA; PERMEABILITY; SERUM; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84895829413     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2013-305907     Document Type: Article

References (40)

1. Jarius S, Wildemann B. The history of neuromyelitis optica. J Neuroinflammation 2013;10:8.
2. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;264:2106-12. (Pubitemid 39626806)
3. Hinson SR, Pittock SJ, Lucchinetti CF, et al. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology 2007;69:2221-31. (Pubitemid 350294677)
4. Jarius S, Wildemann B. AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol 2010;6:383-92.
5. Misu T, Fujihara K, Kakita A, et al. Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain 2007;130:1224-34. (Pubitemid 47355951)
6. Takahashi T, Fujihara K, Nakashima I, et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 2007;130:1235-43. (Pubitemid 47355956)
7. Jacob A, McKeon A, Nakashima I, et al. Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders. J Neurol Neurosurg Psychiatry 2013;84:922-30.
8. Papadopoulos MC, Verkman AS. Aquaporin 4 and neuromyelitis optica. Lancet Neurol 2012;11:535-44.
9. Sharma R, Fischer MT, Bauer J, et al. Inflammation induced by innate immunity in the central nervous system leads to primary astrocyte dysfunction followed by demyelination. Acta Neuropathol 2010;120:223-36.
10. Bradl M, Misu T, Takahashi T, et al. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol 2009;66:630-43.
11. Jarius S, Aboul-Enein F, Waters P, et al. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain 2008;131:3072-80.
12. Kim W, Lee JE, Li XF, et al. Quantitative measurement of anti-aquaporin-4 antibodies by enzyme-linked immunosorbent assay using purified recombinant human aquaporin-4. Mult Scler 2012;18:578-86.
13. Uzawa A, Mori M, Masuda S, et al. CSF high-mobility group box 1 is associated with intrathecal inflammation and astrocytic damage in neuromyelitis optica. J Neurol Neurosurg Psychiatry 2013;84:517-22.
14. Vincent T, Saikali P, Cayrol R, et al. Functional consequences of neuromyelitis optica-IgG astrocyte interactions on blood-brain barrier permeability and granulocyte recruitment. J Immunol 2008;181:5730-37.
15. Shimizu F, Sano Y, Takahashi T, et al. Sera from neuromyelitis optica patients disrupt the blood-brain barrier. J Neurol Neurosurg Psychiatry 2012;83:288-97.
16. Hosokawa T, Nakajima H, Doi Y, et al. Increased serum matrix metalloproteinase-9 in neuromyelitis optica: implication of disruption of blood-brain barrier. J Neuroimmunol 2011;236:81-6.
17. Uzawa A, Mori M, Masuda S, et al. Markedly elevated soluble intercellular adhesion molecule 1, soluble vascular cell adhesion molecule 1 levels, and blood-brain barrier breakdown in neuromyelitis optica. Arch Neurol 2011;68:913-17.
18. Leppert D, Ford J, Stabler G, et al. Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis. Brain 1998;121:2327-34. (Pubitemid 28552469)
19. Murphy G, Knäuper V. Relating matrix metalloproteinase structure to function: why the "hemopexin" domain? Matrix Biol 1997;15:511-18. (Pubitemid 27190025)
20. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66:1485-9. (Pubitemid 43958540)
21. Wingerchuk DM, Lennon VA, Lucchinetti CF, et al. The spectrum of neuromyelitis optica. Lancet Neurol 2007;6:805-15. (Pubitemid 47238676)
22. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292-302.
23. Sano Y, Shimizu F, Abe M, et al. Establishment of a new conditionally immortalized human brain microvascular endothelial cell line retaining an in vivo blood-brain barrier function. J Cell Physiol 2010;225:519-28.
24. Haruki H, Sano Y, Shimizu F, et al. NMO sera down-regulate AQP4 in human astrocyte and induce cytotoxicity independent of complement. J Neurol Sci 2013;331:136-44.
25. Abe M, Sano Y, Maeda T, et al. Establishment and characterization of human peripheral nerve microvascular endothelial cell lines: a new in vitro blood-nerve barrier (BNB) model. Cell Struct Funct 2012;37:89-100.
26. Saito K, Shimizu F, Koga M, et al. Blood-brain barrier destruction determines Fisher/Bickerstaff clinical phenotypes: an in vitro study. J Neurol Neurosurg Psychiatry 2013;84:756-65.
27. Shimizu F, Sano Y, Tominaga O, et al. Advanced glycation end-products disrupt the blood-brain barrier by stimulating the release of transforming growth factor-β by pericytes and vascular endothelial growth factor and matrix metalloproteinase-2 by endothelial cells in vitro. Neurobiol Aging 2013;34:1902-12.
28. Jarius S, Franciotta D, Paul F, et al. Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance. J Neuroinflammation 2010;7:52.
29. Kinoshita M, Nakatsuji Y, Kimura T, et al. Anti-aquaporin-4 antibody induces astrocytic cytotoxicity in the absence of CNS antigen-specific T cells. Biochem Biophys Res Commun 2010;394:205-10.
30. Saadoun S, Waters P, Bell BA, et al. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 2010;133:349-61.
31. Jarius S, Paul F, Franciotta D, et al. Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures. J Neurol Sci 2011;306:82-90.
32. Gijbels K, Galargy RE, Steinman L. Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteinases. J Clin Invest 1994;94:2177-82. (Pubitemid 24379586)
33. Augé F, Hornebeck W, Decarme M, et al. Improved gelatinase a selectivity by novel zinc binding groups containing galardin derivatives. Bioorg Med Chem Lett 2003;13:1783-6. (Pubitemid 36561164)
34. Engelhardt B. T cell migration into the central nervous system during health and disease: different molecular keys allow access to different central nervous system compartments. Clin Exp Neuroimmunol 2010;1:79-93.
35. Takeshita Y, Ransohoff RM. Inflammatory cell trafficking across the blood-brain barrier: chemokine regulation and in vitro models. Immunol Rev 2012;248: 228-39.
36. Engelhardt B, Kappos L. Natalizumab: targeting alpha4-integrins in multiple sclerosis. Neurodegener Dis 2008;5:16-22. (Pubitemid 350261811)
37. Miller DH, Soon D, Fernando KT, et al. AFFIRM Investigators. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology 2007;68:1390-401. (Pubitemid 46659091)
38. Barnett MH, Prineas JW, Buckland ME, et al. Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy. Mult Scler 2012;18:108-12.
39. Kleiter I, Hellwig K, Berthele A, et al. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol 2012;69:239-45.
40. Jacob A, Hutchinson M, Elsone L, et al. Does natalizumab therapy worsen neuromyelitis optica? Neurology 2012;79:1065-6.